MedTrace Logo

Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis

NCT01538849 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2014-07-10

No results posted yet for this study

Summary

This study is to investigate the optimal clinical dose and administration methods of YH4808 in patients with reflux esophagitis by evaluating the safety and efficacy after YH4808 oral administration.

Conditions

  • Reflux Esophagitis

Interventions

DRUG

Esomeprazole 40mg

1 tablet = Esomeprazole 40 mg

DRUG

YH4808 A mg

1 tablet = YH4808 A mg

DRUG

YH4808 B mg

1 tablet = YH4808 B mg

DRUG

YH4808 C mg

YH4808 C mg = 2 x YH4808 B mg

Sponsors & Collaborators

  • Yuhan Corporation

    lead INDUSTRY

Principal Investigators

  • Myung Gyy Choi, M.D., Ph.D. · Catholic Univ. Seoul St. Mary Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-11-30
Completion
2014-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01538849 on ClinicalTrials.gov